September 29, 2025 - 10:15

Recent analysis indicates that Betmakers Technology Group's shares could be trading at approximately 37% below their intrinsic value estimate. Utilizing the two-stage free cash flow to equity model, the fair value estimate for the company's shares is calculated to be around AU$0.32.
This valuation suggests that investors may have an opportunity to acquire shares at a discount, making it a potentially attractive investment. The two-stage model takes into account the company's expected growth rates and cash flow projections, providing a comprehensive view of its financial health and future potential.
Betmakers Technology Group operates in the rapidly evolving sports betting and technology sector, which has seen significant growth in recent years. As the market continues to expand, the company is well-positioned to capitalize on emerging opportunities. Investors may want to closely monitor developments within the company and the industry as a whole, as these factors could influence future share performance.
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...